IONS241220P27500
- 0.00
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $75
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $61
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $62
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $45 to $77
Ionis Pharmaceuticals: Promising Pipeline and Strategic Milestones Drive Buy Rating
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $51 to $77
RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT) and Cytokinetics (CYTK)
Ionis Pharmaceuticals (IONS) Gets a Hold From Barclays
Ionis Pharmaceuticals: Strategic Developments and Robust Pipeline Justify Buy Rating
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
Ionis Pharmaceuticals (IONS) Receives a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $55
Ionis Pharmaceuticals Analyst Ratings
Guggenheim Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $65